Aurora Spine Dirección

Dirección controles de criterios 3/4

El CEO de Aurora Spine's es Trent Northcutt , nombrado en Feb 2012, tiene una permanencia de 12.17 años. compensación anual total es $122.89K, compuesta por 86% salario y 14% primas, incluidas acciones y opciones de la empresa. posee directamente un 6.8% de las acciones de la empresa, por valor de CA$1.57M. La antigüedad media del equipo directivo y de la junta directiva es de 11.3 años y 10.8 años, respectivamente.

Información clave

Trent Northcutt

Chief Executive Officer (CEO)

US$175.2k

Compensación total

Porcentaje del salario del CEO	77.8%
Permanencia del CEO	12.3yrs
Participación del CEO	6.8%
Permanencia media de la dirección	11.4yrs
Promedio de permanencia en la Junta Directiva	10.9yrs

Actualizaciones recientes de la dirección

Recent updates

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aug 11

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

May 01

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Dec 22

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aug 23

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

May 04

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Dec 23

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Jun 11

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

Feb 26

Is Aurora Spine (CVE:ASG) A Risky Investment?

Nov 19

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Trent Northcutt en comparación con los beneficios de Aurora Spine?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$1m
Dec 31 2023	US$175k	US$136k	-US$2m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$123k	US$106k	-US$2m
Sep 30 2022	n/a	n/a	-US$2m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	n/a	n/a	-US$2m
Dec 31 2021	US$127k	US$111k	-US$2m
Sep 30 2021	n/a	n/a	-US$1m
Jun 30 2021	n/a	n/a	-US$793k
Mar 31 2021	n/a	n/a	-US$58k
Dec 31 2020	US$143k	US$131k	-US$232k
Sep 30 2020	n/a	n/a	-US$777k
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	n/a	n/a	-US$2m
Dec 31 2019	US$143k	US$131k	-US$1m
Sep 30 2019	n/a	n/a	-US$756k
Jun 30 2019	n/a	n/a	-US$199k
Mar 31 2019	n/a	n/a	-US$114k
Dec 31 2018	US$157k	US$125k	-US$68k
Sep 30 2018	n/a	n/a	-US$877k
Jun 30 2018	n/a	n/a	-US$1m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$137k	US$125k	-US$2m

Compensación vs. Mercado: La compensación total ($USD122.89K) de Trent está en línea con el promedio de empresas de tamaño similar en el mercado Canadian ($USD175.49K).

Compensación vs. Ingresos: La compensación de Trent ha aumentado mientras la empresa no es rentable.

CEO

Trent Northcutt (57 yo)

12.3yrs

Permanencia

US$175,227

Compensación

Mr. Trent J. Northcutt is the Chief Executive Officer and President at Aurora Spine Corporation since February 2012. He is a Founder of Aurora Spine Corporation. Mr. Northcutt served as Vice President at S...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Trent Northcutt	Founder	12.3yrs	US$175.23k	6.84% $ 1.4m
Chad Clouse	Chief Financial Officer	3.9yrs	US$168.37k	0.0078% $ 1.6k
Laszlo Garamszegi	CTO & Founder	11.4yrs	US$151.07k	sin datos
David Meyer	VP, Chief Legal Officer & Secretary	no data	US$143.07k	sin datos
Matthew Goldstone	Chief Commercial Officer	no data	sin datos	sin datos

11.4yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de ASG es experimentado (11.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Trent Northcutt	Founder	10.9yrs	US$175.23k	6.84% $ 1.4m
David Rosenkrantz	Independent Chairman	10.9yrs	sin datos	15.97% $ 3.2m
Tracy Graf	Independent Director	10.9yrs	sin datos	0.55% $ 109.2k
Joseph MacLellan	Independent Director	10.9yrs	sin datos	0.94% $ 189.0k
James Snow	Independent Director	10.9yrs	sin datos	0.78% $ 155.8k
Michael Seid	Independent Director	10.9yrs	sin datos	0.13% $ 25.2k

10.9yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de ASG son experimentados ( 10.8 años antigüedad media).

Aurora Spine Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

Independent Director recently sold CA$135k worth of stock

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Independent Chairman exercised options to buy CA$355k worth of stock.

Insufficient new directors

Recent updates

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

First quarter 2021 earnings released: US$0.01 loss per share (vs US$0.011 loss in 1Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Receives Irb Approval to Commence Registration for Multicenter Study of Its Silo™ Device for Si Joint Pain

Full year 2020 earnings released

Aurora Spine Corporation Announces Launch of its SiLOTM Posterior SI Joint Fusion System

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

New 90-day high: CA$0.53

Aurora Spine Corporation(TSXV:ASG) dropped from S&P/TSX Venture Composite Index

New 90-day high: CA$0.44

New 90-day high: CA$0.38

Aurora Spine Plans A Major Multicenter Study of Its ZIPTM Interspinous Fixation Device for Relief of Back Pain

New 90-day high: CA$0.36

Third quarter 2020 earnings released: EPS US$0.01

Is Aurora Spine (CVE:ASG) A Risky Investment?

Aurora Spine Corporation Announces Commercial Launch of The SOLO™ System

New 90-day high: CA$0.31

First half earnings released